Principal Investigator: Professor Liam Heaney

Name of the Study: BP44551

Why is this Study important?

Despite the availability of effective treatments, asthma still causes significant disease burden and mortality. New treatments are needed to address this unmet need.

What is the Research question/aim?: 

A study to address airway inflammation in patients with moderate to severe asthma, to compare the safety and effectiveness of selnoflast with a placebo, understand how the body processes it and to establish if selnoflast improves people's breathing and quality of life.

What the Study involves:

Over approximately 11 weeks, eligible participants will commence a 3-week screening period to assess their eligibility to take part. A treatment period of six weeks then follows, during which participants will receive either selnoflast or a placebo. Two weeks after treatment, following the cessation of the drug, a follow-up visit will take place. These clinic visits will include checks to see how the participant responds to the treatment and any side effects they may have.

Who can take part in the Study?

People aged 18–80yrss old who have been diagnosed with asthma for at least 1 year. People must also be taking certain treatments for asthma for at least 3 months, including an ICS and a long-acting (slow-release) bronchodilator. Participants must not have smoked for at least 6 months.

Contact Information:

Sharon Carr – Lead Early Phase Research Nurse

Email: sharon.carr@belfasttrust.hscni.net

Tel: 02895040342

Northern Ireland Clinical Research Facility (NICRF)

U Floor, Belfast City Hospital

51 Lisburn Road

Belfast BT9 7AB